Nanomedicines for renal disease: current status and future applications

Nazila Kamaly; John C. He; Dennis A. Ausiello; Omid C. Farokhzad

doi:10.1038/nrneph.2016.156

journal article Oct 31, 2016

Nanomedicines for renal disease: current status and future applications

Nazila Kamaly

John C. He Dennis A. Ausiello Omid C. Farokhzad

Nature Reviews Nephrology Vol. 12 No. 12 pp. 738-753 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrneph.2016.156

Topics

No keywords indexed for this article. Browse by subject →

References

301

[1]

Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16–20 (2009). 10.1021/nn900002m

[2]

Nanocarriers as an emerging platform for cancer therapy

Dan Peer, Jeffrey M. Karp, Seungpyo Hong et al.

Nature Nanotechnology 2007 10.1038/nnano.2007.387

[3]

Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185–198 (2012). 10.1146/annurev-med-040210-162544

[4]

Heath, J. R. & Davis, M. E. Nanotechnology and cancer. Annu. Rev. Med. 59, 251–265 (2008). 10.1146/annurev.med.59.061506.185523

[5]

Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). 10.1038/nrd2614

[6]

Wang, J., Byrne, J. D., Napier, M. E. & DeSimone, J. M. More effective nanomedicines through particle design. Small 7, 1919–1931 (2011). 10.1002/smll.201100442

[7]

Saha, K., Bajaj, A., Duncan, B. & Rotello, V. M. Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and bio-macromolecules. Small 7, 1903–1918 (2011). 10.1002/smll.201100478

[8]

Mu, Q. et al. Chemical basis of interactions between engineered nanoparticles and biological systems. Chem. Rev. 114, 7740–7781 (2014). 10.1021/cr400295a

[9]

Albanese, A. et al. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. ACS Nano 8, 5515–5526 (2014). 10.1021/nn4061012

[10]

Understanding biophysicochemical interactions at the nano–bio interface

Andre E. Nel, Lutz Mädler, Darrell Velegol et al.

Nature Materials 2009 10.1038/nmat2442

[11]

Gratton, S. E. et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105, 11613–11618 (2008). 10.1073/pnas.0801763105

[12]

Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41, 2971–3010 (2012). 10.1039/c2cs15344k

[13]

Anselmo, A. C. & Mitragotri, S. Impact of particle elasticity on particle-based drug delivery systems. Adv. Drug Deliv. Rev. http://dx.doi.org/10.1016/j.addr.2016.01.007 (2016). 10.1016/j.addr.2016.01.007

[14]

Marty, J. J., Oppenheim, R. C. & Speiser, P. Nanoparticles — a new colloidal drug delivery system. Pharm. Acta Helv. 53, 17–23 (1978).

[15]

Shi, J., Xiao, Z., Kamaly, N. & Farokhzad, O. C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44, 1123–1134 (2011). 10.1021/ar200054n

[16]

Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy

Guanying Chen, Indrajit Roy, Chunhui Yang et al.

Chemical Reviews 2016 10.1021/acs.chemrev.5b00148

[17]

Emerging applications of stimuli-responsive polymer materials

Martien A. Cohen Stuart, Wilhelm T. S. Huck, Jan Genzer et al.

Nature Materials 2010 10.1038/nmat2614

[18]

Pacardo, D. B., Ligler, F. S. & Gu, Z. Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale 7, 3381–3391 (2015). 10.1039/c4nr07677j

[19]

Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991–1003 (2013). 10.1038/nmat3776

[20]

Koetting, M. C., Peters, J. T., Steichen, S. D. & Peppas, N. A. Stimulus-responsive hydrogels: theory, modern advances, and applications. Mater. Sci. Eng. R. Rep. 93, 1–49 (2015). 10.1016/j.mser.2015.04.001

[21]

Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 13, 813–827 (2014). 10.1038/nrd4333

[22]

de la Rica, R., Aili, D. & Stevens, M. M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 64, 967–978 (2012). 10.1016/j.addr.2012.01.002

[23]

Correa, S., Dreaden, E. C., Gu, L. & Hammond, P. T. Engineering nanolayered particles for modular drug delivery. J. Control. Release 240, 364–386 (2016). 10.1016/j.jconrel.2016.01.040

[24]

Kemp, J. A., Shim, M. S., Heo, C. Y. & Kwon, Y. J. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv. Drug Deliv. Rev. 98, 3–18 (2016). 10.1016/j.addr.2015.10.019

[25]

Xu, X., Ho, W., Zhang, X., Bertrand, N. & Farokhzad, O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med. 21, 223–232 (2015). 10.1016/j.molmed.2015.01.001

[26]

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia M. LoRusso et al.

Cancer Discovery 2013 10.1158/2159-8290.cd-12-0429

[27]

Reddy, L. H. & Couvreur, P. Nanotechnology for therapy and imaging of liver diseases. J. Hepatol. 55, 1461–1466 (2011). 10.1016/j.jhep.2011.05.039

[28]

Wang, A. Z. et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 8, 1063–1070 (2008). 10.1517/14712598.8.8.1063

[29]

Lyseng-Williamson, K. A., Duggan, S. T. & Keating, G. M. Pegylated liposomal doxorubicin: a guide to its use in various malignancies. BioDrugs 27, 533–540 (2013). 10.1007/s40259-013-0070-1

[30]

Doxil® — The first FDA-approved nano-drug: Lessons learned

Yechezkel (Chezy) Barenholz

Journal of Controlled Release 2012 10.1016/j.jconrel.2012.03.020

[31]

Harrison, M., Tomlinson, D. & Stewart, S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13, 914–920 (1995). 10.1200/jco.1995.13.4.914

[32]

Money-Kyrle, J. F. et al. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin. Oncol. 5, 367–371 (1993). 10.1016/s0936-6555(05)80088-3

[33]

Rosenthal, E. et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. J. Clin. Oncol. 25, 57–59 (2002). 10.1097/00000421-200202000-00012

[34]

Meyerhoff, A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28, 42–48 (1999). 10.1086/515085

[35]

Khemapech, N., Oranratanaphan, S., Termrungruanglert, W., Lertkhachonsuk, R. & Vasurattana, A. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (Lipo-Dox®). Asian Pac. J. Cancer Prev. 14, 2131–2135 (2013). 10.7314/apjcp.2013.14.3.2131

[36]

Glantz, M. J. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394–3402 (1999).

[37]

Batist, G. et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 1444–1454 (2001). 10.1200/jco.2001.19.5.1444

[38]

Agosta, E. et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics 13, 1037–1053 (2012). 10.2217/pgs.12.77

[39]

Gabizon, A. et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother. Pharmacol. 61, 695–702 (2008). 10.1007/s00280-007-0525-5

[40]

Gambling, D., Hughes, T., Martin, G., Horton, W. & Manvelian, G. A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth. Analg. 100, 1065–1074 (2005). 10.1213/01.ane.0000145009.03574.78

[41]

Venkatakrishnan, K. et al. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. Br. J. Clin. Pharmacol. 77, 998–1010 (2014). 10.1111/bcp.12261

[42]

Ingram, I. FDA approves liposomal vincristine (Marqibo) for rare leukemia. Oncology (Williston Park) 26, 841 (2012).

[43]

Silverman, J. A. & Deitcher, S. R. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 71, 555–564 (2013). 10.1007/s00280-012-2042-4

[44]

Liposomal drug delivery systems: From concept to clinical applications

Pieter R. Cullis

Advanced Drug Delivery Reviews 2013 10.1016/j.addr.2012.09.037

[45]

Gabizon, A., Shmeeda, H. & Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419–436 (2003). 10.2165/00003088-200342050-00002

[46]

Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132, 171–183 (2008). 10.1016/j.jconrel.2008.05.010

[47]

Singla, A. K., Garg, A. & Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 235, 179–192 (2002). 10.1016/s0378-5173(01)00986-3

[48]

Kundranda, M. N. & Niu, J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des. Devel. Ther. 9, 3767–3777 (2015). 10.2147/dddt.s88023

[49]

Liu, Z. & Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 45, 1432–1456 (2016). 10.1039/c5cs00158g

[50]

Ibrahim, N. K. et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23, 6019–6026 (2005). 10.1200/jco.2005.11.013

Showing 50 of 301 references

Cited By

218

Engineered macrophage membrane-coated nanoparticles attenuate calcium oxalate nephrocalcinosis-induced kidney injury by reducing oxidative stress and pyroptosis

Xiaozhuo Ba, Tao Ye · 2025

Acta Biomaterialia

Microneedles loaded with cerium-manganese oxide nanoparticles for targeting macrophages in the treatment of rheumatoid arthritis

Tian Xia, Yuting Zhu · 2024

Journal of Nanobiotechnology

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

Arturo Sánchez, Susana P. Mejía · 2020

Molecules

Nanomedicines for Renal Management: From Imaging to Treatment

Dawei Jiang, Zachary T. Rosenkrans · 2020

Accounts of Chemical Research

DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury

Dawei Jiang, Zhilei Ge · 2018

Nature Biomedical Engineering

Metrics

218

Citations

301

References

Details

Published: Oct 31, 2016
Vol/Issue: 12(12)
Pages: 738-753
License: View

Authors

MIT-Harvard Center for Cancer Nanotechnology Excellence; Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115

Cite This Article

Nazila Kamaly, John C. He, Dennis A. Ausiello, et al. (2016). Nanomedicines for renal disease: current status and future applications. Nature Reviews Nephrology, 12(12), 738-753. https://doi.org/10.1038/nrneph.2016.156

Nanomedicines for renal disease: current status and future applications

You May Also Like